Do analysts recommend ENVB or TRIB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Trinity Biotech 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts prefer INM or TRIB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Trinity Biotech 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media prefer INM or TRIB?

In the previous week, Trinity Biotech had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 5 mentions for Trinity Biotech and 4 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.75 beat Trinity Biotech's score of 0.32 indicating that InMed Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trinity Biotech 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate DRMA or TRIB?

Dermata Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 646.27%. Given Dermata Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Dermata Therapeutics is more favorable than Trinity Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Trinity Biotech 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts rate ALZN or TRIB?

Alzamend Neuro presently has a consensus target price of $28.00, suggesting a potential upside of 2,313.79%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, equities research analysts plainly believe Alzamend Neuro is more favorable than Trinity Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alzamend Neuro 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Trinity Biotech 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts recommend LIMN or TRIB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Trinity Biotech 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is LIMN or TRIB more profitable?

Liminatus Pharma has a net margin of 0.00% compared to Trinity Biotech's net margin of -70.06%. Company Net Margins Return on Equity Return on Assets Liminatus Pharma N/A N/A -299.79% Trinity Biotech -70.06% N/A -32.13%

Does the media prefer LIMN or TRIB?

In the previous week, Trinity Biotech had 2 more articles in the media than Liminatus Pharma. MarketBeat recorded 5 mentions for Trinity Biotech and 3 mentions for Liminatus Pharma. Liminatus Pharma's average media sentiment score of 0.64 beat Trinity Biotech's score of 0.32 indicating that Liminatus Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liminatus Pharma 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trinity Biotech 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Trinity Biotech (TRIB) Competitors

$0.38 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$0.36 -0.01 (-3.32%)

As of 07/2/2026 07:57 PM Eastern

Compare

TRIB vs. ENVB, INM, DRMA, ALZN, and LIMN

Should you buy Trinity Biotech stock or one of its competitors? MarketBeat compares Trinity Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Trinity Biotech include Enveric Biosciences (ENVB), InMed Pharmaceuticals (INM), Dermata Therapeutics (DRMA), Alzamend Neuro (ALZN), and Liminatus Pharma (LIMN). These companies are all part of the "pharmaceutical products" industry.

How does Trinity Biotech compare to Enveric Biosciences?

Enveric Biosciences (NASDAQ:ENVB) and Trinity Biotech (NASDAQ:TRIB) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Enveric Biosciences has a net margin of 0.00% compared to Trinity Biotech's net margin of -70.06%. Trinity Biotech's return on equity of 0.00% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	N/A	-220.97%	-177.47%
Trinity Biotech	-70.06%	N/A	-32.13%

Enveric Biosciences has higher earnings, but lower revenue than Trinity Biotech. Trinity Biotech is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A
Trinity Biotech	$43.78M	0.03	-$37.38M	-$1.73	N/A

In the previous week, Trinity Biotech had 5 more articles in the media than Enveric Biosciences. MarketBeat recorded 5 mentions for Trinity Biotech and 0 mentions for Enveric Biosciences. Trinity Biotech's average media sentiment score of 0.32 beat Enveric Biosciences' score of -0.35 indicating that Trinity Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Enveric Biosciences	Neutral
Trinity Biotech	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Trinity Biotech	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

13.8% of Enveric Biosciences shares are owned by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are owned by institutional investors. 2.4% of Enveric Biosciences shares are owned by company insiders. Comparatively, 8.2% of Trinity Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Trinity Biotech beats Enveric Biosciences on 9 of the 12 factors compared between the two stocks.

How does Trinity Biotech compare to InMed Pharmaceuticals?

InMed Pharmaceuticals (NASDAQ:INM) and Trinity Biotech (NASDAQ:TRIB) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are owned by institutional investors. 0.9% of InMed Pharmaceuticals shares are owned by insiders. Comparatively, 8.2% of Trinity Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Trinity Biotech has a net margin of -70.06% compared to InMed Pharmaceuticals' net margin of -132.87%. Trinity Biotech's return on equity of 0.00% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Trinity Biotech	-70.06%	N/A	-32.13%

InMed Pharmaceuticals has higher earnings, but lower revenue than Trinity Biotech. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	1.05	-$8.16M	-$2.89	N/A
Trinity Biotech	$43.78M	0.03	-$37.38M	-$1.73	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Trinity Biotech	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Trinity Biotech had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 5 mentions for Trinity Biotech and 4 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.75 beat Trinity Biotech's score of 0.32 indicating that InMed Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trinity Biotech	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Trinity Biotech beats InMed Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Trinity Biotech compare to Dermata Therapeutics?

Dermata Therapeutics (NASDAQ:DRMA) and Trinity Biotech (NASDAQ:TRIB) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Dermata Therapeutics has higher earnings, but lower revenue than Trinity Biotech. Dermata Therapeutics is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$7.56M	-$5.31	N/A
Trinity Biotech	$43.78M	0.03	-$37.38M	-$1.73	N/A

8.7% of Dermata Therapeutics shares are owned by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are owned by institutional investors. 21.9% of Dermata Therapeutics shares are owned by insiders. Comparatively, 8.2% of Trinity Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Dermata Therapeutics has a net margin of 0.00% compared to Trinity Biotech's net margin of -70.06%. Trinity Biotech's return on equity of 0.00% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-127.91%	-105.05%
Trinity Biotech	-70.06%	N/A	-32.13%

Dermata Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 646.27%. Given Dermata Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Dermata Therapeutics is more favorable than Trinity Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Trinity Biotech	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Trinity Biotech had 5 more articles in the media than Dermata Therapeutics. MarketBeat recorded 5 mentions for Trinity Biotech and 0 mentions for Dermata Therapeutics. Trinity Biotech's average media sentiment score of 0.32 beat Dermata Therapeutics' score of 0.00 indicating that Trinity Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Dermata Therapeutics	Neutral
Trinity Biotech	Neutral

Summary

Trinity Biotech beats Dermata Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Trinity Biotech compare to Alzamend Neuro?

Alzamend Neuro (NASDAQ:ALZN) and Trinity Biotech (NASDAQ:TRIB) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Alzamend Neuro has a net margin of 0.00% compared to Trinity Biotech's net margin of -70.06%. Trinity Biotech's return on equity of 0.00% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-177.52%	-140.41%
Trinity Biotech	-70.06%	N/A	-32.13%

49.6% of Alzamend Neuro shares are held by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are held by institutional investors. 1.4% of Alzamend Neuro shares are held by insiders. Comparatively, 8.2% of Trinity Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Alzamend Neuro has higher earnings, but lower revenue than Trinity Biotech. Alzamend Neuro is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A
Trinity Biotech	$43.78M	0.03	-$37.38M	-$1.73	N/A

Alzamend Neuro presently has a consensus target price of $28.00, suggesting a potential upside of 2,313.79%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, equities research analysts plainly believe Alzamend Neuro is more favorable than Trinity Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Trinity Biotech	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Trinity Biotech had 5 more articles in the media than Alzamend Neuro. MarketBeat recorded 5 mentions for Trinity Biotech and 0 mentions for Alzamend Neuro. Trinity Biotech's average media sentiment score of 0.32 beat Alzamend Neuro's score of 0.00 indicating that Trinity Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Alzamend Neuro	Neutral
Trinity Biotech	Neutral

Summary

Trinity Biotech beats Alzamend Neuro on 9 of the 14 factors compared between the two stocks.

How does Trinity Biotech compare to Liminatus Pharma?

Liminatus Pharma (NASDAQ:LIMN) and Trinity Biotech (NASDAQ:TRIB) are both pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Trinity Biotech	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

79.0% of Trinity Biotech shares are owned by institutional investors. 8.2% of Trinity Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Trinity Biotech had 2 more articles in the media than Liminatus Pharma. MarketBeat recorded 5 mentions for Trinity Biotech and 3 mentions for Liminatus Pharma. Liminatus Pharma's average media sentiment score of 0.64 beat Trinity Biotech's score of 0.32 indicating that Liminatus Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liminatus Pharma	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trinity Biotech	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Liminatus Pharma has a net margin of 0.00% compared to Trinity Biotech's net margin of -70.06%.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-299.79%
Trinity Biotech	-70.06%	N/A	-32.13%

Liminatus Pharma has higher earnings, but lower revenue than Trinity Biotech. Liminatus Pharma is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A
Trinity Biotech	$43.78M	0.03	-$37.38M	-$1.73	N/A

Summary

Trinity Biotech beats Liminatus Pharma on 7 of the 11 factors compared between the two stocks.

Get Trinity Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRIB vs. The Competition

Export

Metric	Trinity Biotech	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	N/A	$8.69B	$7.16B	$12.48B
Dividend Yield	N/A	2.45%	2.66%	6.52%
P/E Ratio	-0.22	16.55	28.02	24.70
Price / Sales	0.03	6.06	540.37	99.49
Price / Cash	N/A	18.11	49.26	57.09
Price / Book	-0.02	3.53	10.96	6.46
Net Income	-$37.38M	$226.25M	$3.57B	$337.01M
7 Day Performance	4.29%	1.50%	2.12%	1.69%
1 Month Performance	-43.60%	-0.23%	5.25%	3.81%
1 Year Performance	-89.36%	-0.49%	33.29%	23.90%

Trinity Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRIB Trinity Biotech	1.2895 of 5 stars	$0.38 flat	N/A	-89.4%	$0.00	$43.78M	N/A	480	Short Interest Decrease Gap Down High Trading Volume
ENVB Enveric Biosciences	0.5205 of 5 stars	$1.38 +3.4%	N/A	-90.4%	$5.06M	N/A	N/A	20	Short Interest Increase Gap Up
INM InMed Pharmaceuticals	1.7456 of 5 stars	$1.50 -0.3%	N/A	-46.2%	$4.95M	$4.94M	N/A	10
DRMA Dermata Therapeutics	2.6185 of 5 stars	$1.23 -0.4%	$10.00 +716.3%	-79.9%	$4.92M	N/A	N/A	8	Positive News
ALZN Alzamend Neuro	3.6113 of 5 stars	$1.29 +5.3%	$28.00 +2,079.0%	-60.9%	$4.89M	N/A	N/A	4	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRIB) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trinity Biotech (TRIB) Competitors

TRIB vs. ENVB, INM, DRMA, ALZN, and LIMN

How does Trinity Biotech compare to Enveric Biosciences?

Summary

How does Trinity Biotech compare to InMed Pharmaceuticals?

Summary

How does Trinity Biotech compare to Dermata Therapeutics?

Summary

How does Trinity Biotech compare to Alzamend Neuro?

Summary

How does Trinity Biotech compare to Liminatus Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRIB vs. The Competition

Trinity Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Trinity Biotech (TRIB) Competitors

TRIB vs. ENVB, INM, DRMA, ALZN, and LIMN

How does Trinity Biotech compare to Enveric Biosciences?

Is ENVB or TRIB more profitable?

Which has higher earnings and valuation, ENVB or TRIB?

Does the media favor ENVB or TRIB?

Do analysts recommend ENVB or TRIB?

Do institutionals and insiders hold more shares of ENVB or TRIB?

Summary

How does Trinity Biotech compare to InMed Pharmaceuticals?

Do institutionals and insiders believe in INM or TRIB?

Is INM or TRIB more profitable?

Which has better earnings & valuation, INM or TRIB?

Do analysts prefer INM or TRIB?

Does the media prefer INM or TRIB?

Summary

How does Trinity Biotech compare to Dermata Therapeutics?

Which has higher earnings & valuation, DRMA or TRIB?

Do insiders and institutionals have more ownership in DRMA or TRIB?

Is DRMA or TRIB more profitable?

Do analysts rate DRMA or TRIB?

Does the media favor DRMA or TRIB?

Summary

How does Trinity Biotech compare to Alzamend Neuro?

Is ALZN or TRIB more profitable?

Do insiders & institutionals have more ownership in ALZN or TRIB?

Which has preferable earnings and valuation, ALZN or TRIB?

Do analysts rate ALZN or TRIB?

Does the media favor ALZN or TRIB?

Summary

How does Trinity Biotech compare to Liminatus Pharma?

Do analysts recommend LIMN or TRIB?

Do institutionals & insiders believe in LIMN or TRIB?

Does the media prefer LIMN or TRIB?

Is LIMN or TRIB more profitable?

Which has higher earnings & valuation, LIMN or TRIB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRIB vs. The Competition

Trinity Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools